 Recently,a Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naïve Patients With Advanced-Stage Non-Small- Cell Lung Cancer showed that Overall survival was statistically superior for cisplatin pemetrexed versus cisplatingemcitabine in patients with adenocarcinoma.The result reminded us that patients with adenocarcinoma were most likely to benefit from antifolate drugs. 